A review of patients with relapsing-remitting multiple sclerosis who discontinued fingolimod therapy showed that five out of 46 (10.9 %) of these patients developed a rebound phenomenon between 4 to 16 weeks, where disease activity returns and often exceeds pre-treatment levels.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content